IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v37y2014i10p815-829.html
   My bibliography  Save this article

Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

Author

Listed:
  • Agata Ptaszynska
  • Kristina Johnsson
  • Shamik Parikh
  • Tjerk Bruin
  • Anne Apanovitch
  • James List

Abstract

Dapagliflozin has a favourable and predictable tolerability profile, with reported events related to its mechanism of action. Copyright Springer International Publishing Switzerland 2014

Suggested Citation

  • Agata Ptaszynska & Kristina Johnsson & Shamik Parikh & Tjerk Bruin & Anne Apanovitch & James List, 2014. "Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events," Drug Safety, Springer, vol. 37(10), pages 815-829, October.
    • Handle: RePEc:spr:drugsa:v:37:y:2014:i:10:p:815-829
    DOI: 10.1007/s40264-014-0213-4
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40264-014-0213-4
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40264-014-0213-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Heather E. Danysh & Catherine B. Johannes & Daniel C. Beachler & J. Bradley Layton & Ryan Ziemiecki & Alejandro Arana & Jade Dinh & Ling Li & Brian Calingaert & Manel Pladevall-Vila & Phillip R. Hunt , 2023. "Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting," Drug Safety, Springer, vol. 46(2), pages 175-193, February.
    2. Shuyan Gu & Yiming Mu & Suodi Zhai & Yuhang Zeng & Xuemei Zhen & Hengjin Dong, 2016. "Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-25, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:37:y:2014:i:10:p:815-829. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.